Tosaki Takahiro, Kamiya Hideki, Yamamoto Yuka, Himeno Tatsuhito, Kato Yoshiro, Kondo Masaki, Yamada Yuichiro, Inagaki Akemi, Tsubonaka Kaori, Oshiro Chie, Katayama Takami, Hayasaki Tomoyo, Nakaya Yuki, Fujiyoshi Haruna, Nakamura Jiro
TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan.
Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan.
Intern Med. 2017 Oct 1;56(19):2563-2569. doi: 10.2169/internalmedicine.8184-16. Epub 2017 Sep 6.
Objective We investigated the efficacy, safety, and patient satisfaction of once-weekly DPP-4 inhibitors (DPP-4Is). Methods Either of two once-weekly DPP-4Is, trelagliptin or omarigliptin, was administered alone or in combination with other antidiabetic drugs in 80 outpatients with type 2 diabetes mellitus for 3 months. The HbA1c, glycoalbumin (GA), body weight, and the Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores were evaluated. Results Patients switching from other daily DPP-4Is (n=29) showed no significant changes in the HbA1c or GA levels. However, the HbA1c and GA levels of patients who had been naïve to DPP-4Is (n=37) significantly improved from 9.31±2.53% to 7.02±1.20% (p<0.001) and 26.7±11.8% to 17.3±5.7% (p<0.001), respectively. Several non-serious adverse events were reported, including nausea (n=1), abdominal distension (n=1), and constipation (n=1). In the DTSQs, the total score for six questions on the primary factors representing patient treatment satisfaction was not markedly changed in patients switching from daily to weekly DPP-4Is but was significantly improved from 21.0 to 28.0 (p<0.001) in patients naïve to DPP-4Is. Conclusion These findings suggest that the use of a once-weekly DPP-4I is effective and well-tolerated in diabetes treatment and improves treatment satisfaction.
目的 我们研究了每周一次的二肽基肽酶-4抑制剂（DPP-4Is）的疗效、安全性及患者满意度。方法 将两种每周一次的DPP-4Is（曲格列汀或奥格列汀）之一单独或与其他抗糖尿病药物联合应用于80例2型糖尿病门诊患者，为期3个月。评估糖化血红蛋白（HbA1c）、糖化白蛋白（GA）、体重及糖尿病治疗满意度问卷（DTSQ）得分。结果 从其他每日一次的DPP-4Is转换过来的患者（n = 29），其HbA1c或GA水平无显著变化。然而，既往未使用过DPP-4Is的患者（n = 37），其HbA1c和GA水平分别从9.31±2.53%显著改善至7.02±1.20%（p<0.001）和从26.7±11.8%显著改善至17.3±5.7%（p<0.001）。报告了几例非严重不良事件，包括恶心（n = 1）、腹胀（n = 1）和便秘（n = 1）。在DTSQ中，从每日一次转换为每周一次DPP-4Is的患者，代表患者治疗满意度的六个主要因素问题的总分无明显变化，但既往未使用过DPP-4Is的患者从21.0显著提高至28.0（p<0.001）。结论 这些发现表明，每周一次使用DPP-4I在糖尿病治疗中有效且耐受性良好，并可提高治疗满意度。
